Verdad Capital's research shows biotech stocks heavily owned by multiple specialist funds significantly outperform those with none. This "consensus" among experts acts as a powerful quality screen in a sector where traditional financial metrics are useless, as stocks with zero specialist ownership generate near-zero returns.

The XBI is at post-pandemic highs, but this isn't a true reflection of the entire sector. Its methodology shifted from an equal-weight index to one favoring larger, liquid companies. Recent M&A of these larger companies has disproportionately driven the index up, masking the performance of smaller biotechs.

The current public market isn't an indiscriminate bull run. It rewards strong data and punishes failure, creating an environment where deep-domain specialty investors, who can discern true value, thrive over generalists.

While broad biotech indices performed poorly, the past two years were manageable and even ideal for investors who were highly selective. The downturn created an environment for skilled stock pickers to identify high-quality companies that could withstand market pressures, proving that sector-wide performance is not the whole story.

While the XBI is up significantly, this is driven by under-owned or shorted stocks like Moderna. Meanwhile, the companies most specialist biotech funds actually own are "getting hammered," creating a disconnect between the index's performance and investors' actual portfolio returns.

The strong biotech market performance in 2025 was not a case of a rising tide lifting all boats. Outperformance was concentrated in companies with strong fundamentals and backing from specialist investors, indicating a healthy, discerning market that rewards quality over speculation.

Non-specialist 'tourist investors,' often from the tech sector, are re-entering biotech, attracted by hype around AI and longevity. Their influence is leading to inflated valuations and connecting biotech stock performance to the whims of the tech market. This influx creates risk, as a downturn in tech could disproportionately harm biotech companies funded by this crossover capital.

Despite the biotech index (XBI) appearing relatively stable, many long-short funds are suffering. This is due to a "degrossing effect" and the underperformance of smaller-cap names within the index. The sector, once seen as impervious to rising interest rates, may now be feeling the pressure.

A closer look at biotech ETFs reveals a bifurcated market recovery. The large-cap weighted IBB is back to its late 2021 peak, but the small-cap focused XBI still lags significantly. This shows that investor capital flowing back into the sector is not lifting all boats equally.